- Stocks
- Pharma & Healthcare
- Beryl Drugs
Beryl Drugs share price
NSE: BERLDRGPharma & HealthcareDrug Manufacturers - Specialty & Generic
Beryl Drugs at a glance
With a market capitalisation of ₹11 Cr, it ranks 3852nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 0.0% in FY18. In Q4 FY18, the quarter ended 31 Mar 2018, revenue was ₹4 Cr (+79.0% year on year) and net profit ₹1 Cr, on a consolidated basis. Promoters held 27.82% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹11 CrRank 3852 on NSE
- Price to book
- 0×FY18
- EPS (TTM)
- ₹2.09to Q4 FY18
- ROE
- 0.0%FY18
- ROCE
- 0.0%FY18
- Debt to equity
- 0FY18
- Net profit margin
- 6.2%FY18
- Book value / share
- ₹0.00FY18
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Beryl Drugs quarterly results
| Quarter | Q2 FY17 | Q4 FY17 | Q1 FY18 | Q2 FY18 | Q3 FY18 | Q4 FY18 |
|---|---|---|---|---|---|---|
| Revenue | ₹3 Cr | ₹2 Cr | ₹5 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr |
| Revenue YoY | — | — | — | +7.3% | — | +79.0% |
| Net profit | ₹0 Cr | −₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr |
| Net profit YoY | — | — | — | +440.0% | — | — |
| Net margin | 3.3% | −0.8% | 0.6% | 16.8% | 2.8% | 20.7% |
| EPS | ₹0.20 | — | — | ₹0.16 | ₹0.20 | ₹1.73 |
Beryl Drugs financials
| Item | FY17 | FY18 |
|---|---|---|
| Revenue | ₹12 Cr | ₹16 Cr |
| Operating profit | −₹0 Cr | ₹1 Cr |
| Net profit | −₹0 Cr | ₹1 Cr |
| EPS (₹) | ₹0.00 | ₹2.00 |
| Cash from operations | ₹0 Cr | ₹0 Cr |
| Total debt | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹0 Cr | ₹0 Cr |
Beryl Drugs shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 26.38% | 26.38% | 26.38% | 26.38% | 27.48% | 27.82% |
| Non-institutions | 73.62% | 73.62% | 73.62% | 73.62% | 72.52% | 72.18% |
Beryl Drugs vs peers
The listed Pharma & Healthcare companies nearest to Beryl Drugs by market capitalisation.
Ask anything about Beryl Drugs
Pivot answers on the live chart with evidence you can check, and tests strategies against BERLDRG's own history. Try: “Why has BERLDRG moved over the last three months?” · “Backtest a 50-day moving-average crossover on BERLDRG over five years” · “Compare BERLDRG with NORRIS on margins and valuation”
Frequently asked questions about Beryl Drugs
What is the market cap of Beryl Drugs?
Beryl Drugs' market capitalisation is ₹11 Cr (₹11 Cr) at the 22 Oct 2026 close, ranking 3852nd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Beryl Drugs?
Return on equity was 0.0% in FY18 and return on capital employed was 0.0% in FY18 (consolidated figures).
Is Beryl Drugs a debt-free company?
Beryl Drugs is close to debt-free: its debt-to-equity ratio was 0 in FY18.
What were Beryl Drugs' latest quarterly results?
For Q4 FY18 (quarter ended 31 Mar 2018), Beryl Drugs reported revenue of ₹4 Cr, +79.0% year on year, and net profit of ₹1 Cr.
What is the shareholding pattern of Beryl Drugs?
As of 30 Jun 2026: promoters 27.82%, non-institutions 72.18%.
Who are Beryl Drugs' competitors?
The listed Pharma & Healthcare companies closest to Beryl Drugs by market cap are Norris Medicine, Dolphin Medical, ORTIN GLOBAL, Global Longlife, Looks Health and Broach Lifecare.
Is Beryl Drugs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Beryl Drugs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BERLDRG against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text